Fast Five Quiz: Test Your Knowledge of Severe Asthma

Zab Mosenifar, MD


July 26, 2019

Mepolizumab is a humanized immunoglobulin G1 kappa monoclonal antibody specific for interleukin 5 (IL-5). Mepolizumab binds to IL-5 and therefore stops IL-5 from binding to its receptor on the surface of eosinophils. Inhibiting IL-5 binding to eosinophils reduces blood, tissue, and sputum eosinophil levels. It is indicated for add-on maintenance treatment of patients with severe asthma aged 12 years or older and with an eosinophilic phenotype.

According to ERS/ATS guidelines, both adults and children with severe allergic asthma should undergo a therapeutic trial of omalizumab. The use of methotrexate in adults or children with severe asthma is not recommended, owing to probable adverse effects and the need to monitor therapy. Because of the development of antibiotic resistance and uncertain clinical benefits, routine use of macrolide antibiotics for the treatment of severe asthma or exacerbations is discouraged.

For more on the treatment of severe asthma, read here.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: